National Health and Health Committee recently released that four drugs and infectious disease prevention and control of two special results to achieve new breakthroughs.
The four new drugs:
1. Nafloxacin Malate Capsules, approved for listing
For the highly resistant "super bacteria" infection 1.1 class of new drug "naloxachine malate capsule" has been officially approved. The drug is novel fluoroquinolones.
2. Anti - cancer drug alvainib, phase II clinical trial kick-off
Avitinib has its own intellectual property rights, and it has started simultaneous clinical researches in both China and the United States. Alvainib is China's first third-generation EGFR target drug that enters clinical research.
3. Composin eye ophthalmic injection, enter the US Phase III clinical
Chengdu Kang Hong Biotechnology Co., Ltd. developed a State Category I new drug composin eye ophthalmic injection that approved by the US Food and Drug Administration (FDA). Phase II clinical trial for age-related macular de-generation, AMD is allowed in the US.
4. Paigebin: Break international monopoly and allowed to go public
On October 15, with independent intellectual property rights and effective treatment of viral hepatitis, long-acting interferon "Paigebin" was officially listed breaking the monopoly of similar foreign products, and significantly reduce the burden of hepatitis patients.
